|
TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
AMIODARONE INCREASES SERUM CONCENTRATION OF THE DRUG
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
ASPIRIN CAN ENHANCE THE EFFECT OF THYROXINE , THYROID HORMONE
|
ASPIRIN CAN ENHANCE THE EFFECT OF THYROXINE , THYROID HORMONE
|
ASPIRIN CAN ENHANCE THE EFFECT OF THYROXINE , THYROID HORMONE
|
ASPIRIN CAN ENHANCE THE EFFECT OF THYROXINE , THYROID HORMONE
|
ASPIRIN CAN ENHANCE THE EFFECT OF THYROXINE , THYROID HORMONE
|
ASPIRIN CAN ENHANCE THE EFFECT OF THYROXINE , THYROID HORMONE
|
ASPIRIN CAN ENHANCE THE EFFECT OF THYROXINE , THYROID HORMONE
|
ASPIRIN CAN ENHANCE THE EFFECT OF THYROXINE , THYROID HORMONE
|
ASPIRIN CAN ENHANCE THE EFFECT OF THYROXINE , THYROID HORMONE
|
ASPIRIN CAN ENHANCE THE EFFECT OF THYROXINE , THYROID HORMONE
|
ASPIRIN CAN ENHANCE THE EFFECT OF THYROXINE , THYROID HORMONE
|
ASPIRIN CAN ENHANCE THE EFFECT OF THYROXINE , THYROID HORMONE
|
THYROID ADMINISTRATION TO A DIGITALIZED, HYPOTHYROID PATIENTS MAY INCREASE THE DOSE REQUIREMENT OF DIGOXIN
|
THYROID ADMINISTRATION TO A DIGITALIZED, HYPOTHYROID PATIENTS MAY INCREASE THE DOSE REQUIREMENT OF DIGOXIN
|
MOLYBDENUM REDUCES THE EFFICACY OF THE DRUG
|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
CHLOROQUINE REDUCES GASTRIC ABSORPTION OF THE DRUG & POSSIBLY THE BIOAVAILABILITY OF THE DRUG
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
IRON SALTS INTERFERE WITH THE ABSORPTION OF THE DRUG: HENCE IT SHOULD BE ADMINISTERED 4 HRS BEFORE IRON CONTAINING SALTS
|
CHOLESTYRAMINE REDUCES ABSORPTION IF GIVEN WITHIN ONE HOUR OF EACH OTHER ORALLY, SO IT SHOULD BE GIVEN EITHER ATLEAST 1 HR BEFORE OR 4-6 HRS AFTER CHOLESTYRAMINE
|
CHOLESTYRAMINE REDUCES ABSORPTION IF GIVEN WITHIN ONE HOUR OF EACH OTHER ORALLY, SO IT SHOULD BE GIVEN EITHER ATLEAST 1 HR BEFORE OR 4-6 HRS AFTER CHOLESTYRAMINE
|
MAGNESIUM CONTAINING SALTS MAY INTERFERE WITH THE ABSORPTION OF THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
THYROID MEDICINES MAY LEAD TO ACCELERATED RESPONSE TO TRICYCLIC ANTIDEPRESSANTS & MY PRECIPITATE CARDAC ARRHYTHMIAS
|
THYROID MEDICINES MAY LEAD TO ACCELERATED RESPONSE TO TRICYCLIC ANTIDEPRESSANTS & MY PRECIPITATE CARDAC ARRHYTHMIAS
|
THYROID MEDICINES MAY LEAD TO ACCELERATED RESPONSE TO TRICYCLIC ANTIDEPRESSANTS & MY PRECIPITATE CARDAC ARRHYTHMIAS
|
THYROID MEDICINES MAY LEAD TO ACCELERATED RESPONSE TO TRICYCLIC ANTIDEPRESSANTS & MY PRECIPITATE CARDAC ARRHYTHMIAS
|
THYROID MEDICINES MAY LEAD TO ACCELERATED RESPONSE TO TRICYCLIC ANTIDEPRESSANTS & MY PRECIPITATE CARDAC ARRHYTHMIAS
|
THYROID MEDICINES MAY LEAD TO ACCELERATED RESPONSE TO TRICYCLIC ANTIDEPRESSANTS & MY PRECIPITATE CARDAC ARRHYTHMIAS
|
THYROID MEDICINES MAY LEAD TO ACCELERATED RESPONSE TO TRICYCLIC ANTIDEPRESSANTS & MY PRECIPITATE CARDAC ARRHYTHMIAS
|